|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A total of 360 paired breast carcinoma and adjacent normal tissue samples from 180 sporadic breast cancer patients were included in the present study and examined for PTEN promoter methylation status by methylation-specific polymerase chain reaction.
|
26754093 |
2016 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Relevance of PTEN loss in brain metastasis formation in breast cancer patients.
|
22429330 |
2012 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We found that seven haplotypes from four haplotype blocks located within three genes (NBS1, PTEN, and BRIP1) were significantly associated with breast cancer risk.
|
23357080 |
2013 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.
|
25773930 |
2015 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These insertions were not found in a series of 35 breast carcinomas that showed a loss of PTEN expression without a detectable alteration of this gene.
|
28513612 |
2017 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth.
|
20060890 |
2010 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutations in genes such as TP53 and PTEN have also been linked with high risk for breast cancer within specific cancer syndromes and rare germline variants in genes such as CHEK2 and ATM have been found to confer modest risk to breast cancer.
|
18258506 |
2008 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Previously undetected germline mutations in BRCA1, BRCA2, CHEK2, TP53, and PTEN that predispose to breast cancer; frequencies of these mutations among families with negative genetic test results.
|
16551709 |
2006 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Recent reports show that PTEN mRNA expression is significantly downregulated in brain metastases compared to primary breast cancer.
|
28688620 |
2017 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Over the past decade mutations discovered in genes such as BRCA1, BRCA2, TP53 and PTEN, have emerged as high-penetrance susceptibility genes and are clinically relevant for determination of breast cancer risk.
|
21461994 |
2011 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The involvement of PTEN in human mammary oncogenesis has been implicated from studies showing that germline PTEN mutation in Cowden disease predisposes to breast cancer, the frequent loss of heterozygosity at the PTEN locus, and reduced PTEN protein levels in sporadic breast cancers.
|
11737885 |
2001 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Further experiments showed Znhit1 affected BC through up-regulating PTEN, along with inactivation of the PI3K/Akt/mTOR pathway.
|
30928405 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
There appeared breast cancer with PTEN loss.
|
28407687 |
2017 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
|
29110152 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
|
30096458 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We thus sought to determine whether BMP2 stimulation alters PTEN protein levels in the breast cancer line, MCF-7.
|
12620973 |
2003 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
It seems that PTEN status determined by protein expression may discriminate between subgroups with poor and good prognosis in premenopausal HR-positive BC patients receiving adjuvant OA.
|
30358192 |
2019 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN and MFN2 protein expressions were negative correlated with Vmax and positively correlated with RI in breast cancer patients.
|
31535669 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In short, reductive PTEN mediated by miR-106b and miR-93 promoted cell progression through PI3K/Akt pathway in breast cancer.
|
28518139 |
2017 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis.
|
30702584 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D.
|
30552672 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The nine coding exons of the PTEN gene were screened for harboring germline mutations using denaturing gradient gel electrophoresis (DGGE) complemented by sequencing, in two subsets of Israeli patients: 12 patients clinically diagnosed with BRRS, and 89 women with an apparent inherited predisposition to breast cancer, some with salient features of CD.
|
12372056 |
2002 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation of downstream targets of the PI3K/AKT signalling pathway.
|
23085752 |
2013 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the effects of 15d-PGJ<sub>2</sub> on the activity of PTEN, the inhibitor of the phosphoinositide 3-kinase (PI3K)-Akt axis, in human breast cancer (MCF-7) cells.
|
29550515 |
2018 |
|
Breast Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
These results suggest that methylation of the PTEN promoter related to both SAM increase and DNMT1 activation contributes to persistent Akt activation and are potential therapeutic targets for reversing TAM resistance in breast cancer.
|
21170675 |
2011 |